The production of tailored biological drugs by genetic engineeringrepresents a significant challenge in the field of natural productchemistry. In this issue ofChem, Bode and co-workers have success-fully developed a biosynthetic production platform for novel syrbac-tin-class proteasome inhibitorsby assembling an NRPS/PKS hybridfrom four different natural megasynthetases.